Close Menu

SpeeDx

Roche will have non-exclusive access to SpeeDx's existing tests and technology to enable expansion of diagnostic products for antibiotic resistance in STIs.

The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.

The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.

FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.  

The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.

New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.

The Australian molecular diagnostics firm will use the funds to accelerate commercial expansion in North America and global markets.

The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.

SpeeDx said it will work with GlaxoSmithKline on tests to support its antibiotic clinical trials, as well as its new product development efforts.

An early user of a new Mycoplasma genitalium and antibiotic resistance test from SpeeDx that uses the Xpert cartridge shared some initial validation data.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.